Finance

Beta
Lists
4521:TYO
Kaken Pharmaceutical Co Ltd
¥3,765.00
-0.53%
(-20.00) 1D
Jun 4, 3:30:00 PM GMT+9  ·   JPY
All symbols
SymbolPriceChange% Change
Generating top insights for 4521...
Open
¥3,805
High
¥3,805
Low
¥3,745
Mkt. cap
166.19B
Avg. vol.
130.39K
Volume
95.50K
Dividend
5.05%
Quarterly dividend
¥47
Ex-dividend date
Mar 30, 2026
P/E ratio
66.58
52-wk high
¥4,445
52-wk low
¥3,540
EPS
¥57
Shares outstanding
39.72M
No. of employees
1K
Open
¥3,805
High
¥3,805
Low
¥3,745
Mkt. cap
166.19B
Avg. vol.
130.39K
Volume
95.50K
Dividend
5.05%
Quarterly dividend
¥47
Ex-dividend date
Mar 30, 2026
P/E ratio
66.58
52-wk high
¥4,445
52-wk low
¥3,540
EPS
¥57
Shares outstanding
39.72M
No. of employees
1K
News stories
From sources across the web
About Kaken Pharmaceutical Co Ltd
CEO-
Employees1.13K
Founded1917
Headquarters-
SectorPharmaceutical industry
Websitekaken.co.jp
Previous reportsAll values in JPY
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in JPY
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
18.87B
20.49B
18.26B
19.25B
Cost of goods sold
9.00B
8.78B
9.01B
10.09B
Cost of revenue
9.00B
8.78B
9.01B
10.09B
Research and development expenses
5.38B
6.29B
3.97B
4.94B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
4.47B
5.23B
4.92B
4.92B
Operating expense
9.86B
11.52B
8.90B
10.62B
Total operating expenses
18.85B
20.30B
17.91B
20.71B
Operating income
16.00M
187.00M
354.00M
-1.46B
Other non operating income
-
-27.00M
34.00M
43.00M
EBT including unusual items
408.00M
988.00M
588.00M
328.00M
EBT excluding unusual items
422.00M
184.00M
598.00M
-1.41B
Income tax expense
137.00M
267.00M
182.00M
-418.00M
Effective tax rate
33.58%
27.02%
-
-127.44%
Other operating expenses
-
-
-
-
Net income
271.00M
721.00M
406.00M
746.00M
Net profit margin
1.44%
3.52%
-
3.87%
Earnings per share
-
-
-
-
Interest and investment income
359.00M
78.00M
324.00M
91.00M
Interest expense
-10.00M
-11.00M
-11.00M
-13.00M
Net interest expenses
349.00M
67.00M
313.00M
78.00M
Depreciation and amortization charges
-
-
-
752.00M
EBITDA
-
922.00M
992.50M
-624.75M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer